TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cryosite Limited ( (AU:CTE) ) just unveiled an update.
Cryosite Limited held its Annual General Meeting, where all resolutions, including the adoption of the remuneration report, the company’s option plan, and the re-election of a director, were carried with significant support. This outcome reflects strong shareholder confidence in the company’s strategic direction and governance, potentially enhancing its market position and stakeholder trust.
The most recent analyst rating on (AU:CTE) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Cryosite Limited stock, see the AU:CTE Stock Forecast page.
More about Cryosite Limited
Cryosite is an Australian company specializing in outsourced clinical trials depot services. Established in 2000, the company excels in clinical trial logistics, managing importation, storage, distribution, and reverse logistics for temperature-sensitive products. Their team consists of highly qualified scientists and clinical trials experts, ensuring efficient and safe trial operations.
Average Trading Volume: 6,159
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$42.95M
For an in-depth examination of CTE stock, go to TipRanks’ Overview page.